Jazz Pharmaceuticals’ (JAZZ) Overweight Rating Reaffirmed at Piper Sandler

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report)‘s stock had its “overweight” rating restated by investment analysts at Piper Sandler in a report released on Thursday,Benzinga reports. They currently have a $163.00 price objective on the specialty pharmaceutical company’s stock, down from their prior price objective of $166.00. Piper Sandler’s price objective would suggest a potential upside of 28.68% from the stock’s previous close.

Several other brokerages have also commented on JAZZ. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Wells Fargo & Company lowered their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Finally, TD Cowen lowered their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $175.33.

Read Our Latest Analysis on Jazz Pharmaceuticals

Jazz Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ:JAZZ opened at $126.67 on Thursday. The firm has a market capitalization of $7.66 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.17. The firm has a fifty day moving average of $113.29 and a 200 day moving average of $110.62.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,110 shares of company stock worth $720,160. 4.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. CWA Asset Management Group LLC bought a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth about $3,197,000. Swedbank AB purchased a new stake in Jazz Pharmaceuticals in the second quarter worth about $106,936,000. Vanguard Group Inc. increased its stake in shares of Jazz Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after purchasing an additional 84,941 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 9.2% in the 1st quarter. Advisors Asset Management Inc. now owns 9,722 shares of the specialty pharmaceutical company’s stock worth $1,171,000 after purchasing an additional 819 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

See Also

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.